Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Georgia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Georgia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Georgia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Eugene Long (NPI 1477996965)

Field	Value
Entity Type	Individual
Organization	Eugene Long
Address	3696 Wheeler Rd
City	Augusta
State	GA
ZIP	30909
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 15, 2013

Payer Source	Total Paid
Medicare	$1.9M
Medicaid	$0

Key Findings

This provider is effectively a single-payer Medicare biller with Total Medicare revenue of $1.9M and no Medicaid billing on file; all utilization and revenue signals in the dataset are driven by Medicare activity rather than state Medicaid business. The absence of Medicaid claims indicates limited engagement with that payer population or Medicaid-covered services in this provider's practice footprint.

Revenue concentration is high: the precomputed top 3 Medicare codes account for 68.8% of this provider's total Medicare revenue, signaling reliance on a small number of high-revenue drug codes rather than a broad mix of office or procedural services. That concentration suggests the practice’s financial performance is closely tied to utilization and reimbursement for a few specialty injectable therapies.

The largest single revenue driver is J9271 (pembrolizumab): $670.8K and 35.2% of Medicare revenue, which makes this code the single biggest contributor to the practice’s Medicare book. While the provider’s national rank on J9271 (65th percentile, rank #640 of 1841) indicates a typical, unremarkable volume relative to peers, the absolute dollar share within this provider’s own portfolio is substantial and operationally material.

J9173 (durvalumab) and J0897 (denosumab) are the other two dominant codes, accounting for $381.3K (20.0%) and $260.3K (13.6%) respectively; together with J9271 these three commercial immuno-oncology and supportive oncology injections make up the precomputed 68.8% share. Notably, J0897 ranks in the 94th percentile nationally (rank #578 of 10057) and is labeled "notably above typical national volume," indicating this provider administers denosumab at volumes well above most peers and may have a relative clinical focus or convenience-based offering that drives high utilization of that agent.

The code mix and descriptions (multiple high-revenue oncology injections such as pembrolizumab, durvalumab, daratumumab, and denosumab, plus chemotherapy administration codes 96413 and 96365/96367) point to a hematology/oncology outpatient infusion practice that delivers systemic cancer therapies and supportive agents. The presence of both high-cost immunotherapy agents and routine infusion/E/M codes (e.g., 99214/99215) implies integrated clinic visits with on-site drug administration rather than a purely consultative role.

On competitive standing, the provider shows a mixed picture: for some codes like J9271 the provider’s volume is typical nationally (65th percentile), while for J0897 and several E/M or infusion add-on codes the provider is in high percentiles (e.g., J0897 at 94th, 99215 at 96th, 96367 at 92nd), reflecting pockets of above-typical activity. These high-percentile codes suggest the provider is a major local deliverer of specific services (notably denosumab and higher-level E/M or repeated infusion services) even if overall national dominance across all oncology drugs is not evident.

Tenure-wise, the provider’s NPI was enumerated on 2013-04-15 (~13 years ago), indicating a well-established billing history and continuity in Medicare reporting that supports interpreting these utilization patterns as stable rather than transient. That duration strengthens confidence that the observed revenue concentration reflects an established service mix rather than a very recent shift.

Operationally, reliance on a few high-revenue injectable drugs creates exposure to changes in drug utilization, reimbursement, or access pathways (e.g., biosimilars, site-of-care shifts). Given that the top three Medicare codes drive 68.8% of Medicare revenue, formulary, prior authorization, or payer policy changes affecting pembrolizumab, durvalumab, or denosumab could materially affect practice revenues. Monitor those agents and related administration codes for trend changes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

69 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	15,600	$40	$670.8K
J9173	Injection, durvalumab, 10 mg	6,150	$60	$381.3K
J0897	Injection, denosumab, 1 mg	14,460	$20	$260.3K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	4,680	$40	$177.8K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	2,510	$30	$65.2K
J1439	Injection, ferric carboxymaltose, 1 mg	53,250	$1	$53.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	520	$90	$48.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	500	$90	$45.1K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	310	$130	$41.4K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	9,970	$1	$19.9K

Showing 1–10 of 69

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 69 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Georgia Distribution

Eugene Long — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Georgia

Full comparison — all codes billed, vs. state median

69 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	17	40	15,200	$40	$767.3K
J9144	5	10	9,450	$40	$321.2K
J9173	1	10	4,420	$60	$274.1K
J0897	19	290	2,460	$20	$90.2K
J1449	3	10	2,640	$30	$74.9K
J0881	12	20	15,200	$1	$37.1K
J1439	5	30	28,130	$1	$32.3K
96413	14	160	170	$90	$20.3K
J9217	75	120	110	$130	$20K
99214	1,544	13,640	120	$80	$17.8K

Showing 1–10 of 69

Related Providers

Other providers that share a Tax Identification Number (TIN) with Eugene Long, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Palmetto Retina Center LLC	SC	Ophthalmology Physician	$0	$10.6M
John Payne	SC	Ophthalmology Physician	$4M	$0
John Wells	SC	Ophthalmology Physician	$3.9M	$0
Joshua Robinson	MI	Ophthalmology Physician	$3.7M	$0
Aaron Flanders	FL	Hematology & Oncology Physician	$3.5M	$0
William Clark	SC	Ophthalmology Physician	$3.3M	$0
Barron Fishburne	SC	Retina Specialist (Ophthalmology) Physician	$3.3M	$0
Jeffrey Gross	SC	Retina Specialist (Ophthalmology) Physician	$3M	$0
David Johnson	SC	Retina Specialist (Ophthalmology) Physician	$3M	$0
Oksana Demediuk	GA	Retina Specialist (Ophthalmology) Physician	$2.9M	$0

Nearby Providers

Other providers in the same ZIP code as Eugene Long, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Faircloth Bakeman Partnership	GA	Oral and Maxillofacial Surgery (Dentist)	$0	$4M
Augusta Obstetrics And Gynecology Specialists, LLC	GA	Obstetrics & Gynecology Physician	$0	$3.7M
Eye Surgery Center Of Augusta, LLC	GA	Ambulatory Surgical Clinic/Center	$3.2M	$0
Pediatricare Pm	GA	Pediatrics Physician	$0	$2.8M
Doctors Hospital Of Augusta LLC	GA	General Acute Care Hospital	$0	$2.2M
Joseph M Still Burn Centers, Inc	GA	Specialist	$0	$2M
Ranjit Dhaliwal	GA	Retina Specialist (Ophthalmology) Physician	$1.9M	$0
Dennis Marcus	GA	Ophthalmology Physician	$1.8M	$0
David Squires	GA	Hematology & Oncology Physician	$1.6M	$0
Aos Surgery Center LLC	GA	Ambulatory Surgical Clinic/Center	$1.1M	$0

Eugene Long — Billing Profile & Reimbursement Data

Sign up for Eugene Long — Billing Profile & Reimbursement Data policy alerts

Eugene Long — Billing Profile & Reimbursement Data

Sign up for Eugene Long — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References